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ABSTRACT
Background: Cytotoxic T lymphocyte-associated antigen
4 (CTLA-4) is a key negative regulator of T lymphocytes
and has been shown to be associated with a number of
autoimmune diseases. The present study was performed
to assess the association between CTLA-4 polymorph-
isms and Behc¸et disease (BD) in Chinese patients.
Methods: Two hundred and twenty-eight BD patients
and 207 controls were analysed for four single nucleotide
polymorphisms (SNPs) (21661A/G, 2318C/T, +49G/A
and CT60G/A) in the CTLA-4 gene by PCR-restriction
fragment length polymorphism (RFLP) analysis. The
association between SNP +49A/G and BD in Chinese
population as well as other ethnic groups was analysed by
meta-analysis.
Results: No association could be detected between
CTLA-4 SNPs or haplotypes and BD. Also, no association
was observed between CTLA-4 polymorphisms and BD
subgroups, stratified by clinical features. A meta-analysis
showed that there was no heterogeneity between studies
(p = 0.60, I2 = 0%) and that CTLA-4 SNP +49 was not
associated with BD (overall effect: Z = 0.26, p = 0.79).
Conclusion: This study and a meta-analysis failed to
demonstrate any association between the tested CTLA-4
polymorphisms and BD.
Behc¸et disease (BD) is a well-known refractory
autoimmune disease, characterised by its classical
triad (recurrent oral aphthous ulceration, genital
ulceration and recurrent uveitis) and skin lesions.
Although the precise aetiology and pathogenesis of
BD are still unknown, a widely accepted hypoth-
esis is that an infectious agent and immunological
abnormalities in genetically susceptible individuals
may be responsible for the initiation and main-
tenance of BD. Genetic susceptibility to BD has
been evidenced by familial cases and a strong
association with HLA-B51.1–3 However, the con-
tribution of HLA-B51 to the overall genetic
susceptibility to BD is estimated to be less than
20%.4 As a complex trait disease, BD may result
from a combination of non-genetic factors and
genetic risk factors with a contribution from a
variety of different genes. Each individual gene
may have a relatively modest effect on the risk of
BD.
Cytotoxic T lymphocyte-associated antigen 4
(CTLA-4), located on human chromosome 2q33, is
a member of the CD28 gene family. It is a key
negative regulator of T lymphocyte and is
expressed predominantly in activated and regula-
tory T lymphocytes.5 6 Numerous studies have
revealed the association of CTLA-4 with autoim-
mune diseases mediated by T lymphocytes, such as
type 1 diabetes mellitus, Hashimoto thyroiditis
and Graves disease,7 8 though there are also some
discrepancies between studies.9 10 Some studies
have revealed an association of one particular
single nucleotide polymorphism (SNP) (rs231775)
in CTLA-4 with BD.11 12 However, this association
could not be confirmed by other studies.13 In order
to avoid the one-sidedness of association identified
by one SNP, the present study investigated the
association of four CTLA-4 SNPs (21661A/G,
rs4553808; 2318C/T, rs5742909; +49G/A,
rs231775; and CT60G/A, rs3087243) with BD in a
cohort of Chinese patients. Additionally, a meta-
analysis of the available data from the literature
was also performed. The combined results failed to
show any association between the currently
known CTLA-4 polymorphisms with BD.
PATIENTS AND HEALTHY CONTROLS
Two hundred and twenty-eight unrelated patients
were recruited from the Uveitis Study Center of
Sun Yat-sen University, and the First Affiliated
Hospital of Chongqing Medical University, China.
All the patients fulfilled the International Study
Group criteria for diagnosis of BD or the revised
criteria from Behc¸et disease Research Committee of
Japan if oral ulceration was not present.14 Controls
(n = 207) included age- and ethnic-matched
healthy individuals. All patients and controls were
Han Chinese. The clinical characteristics of the BD
patients included in our study are presented in
table 1. Informed consent was obtained from
patients and controls. This study was approved
by the Ethics Committee of Zhongshan
Ophthalmic Center and the First Affiliated
Hospital of Chongqing Medical University, and
complied with the tenets of the Declaration of
Helsinki.
DNA EXTRACTION
Peripheral blood samples were collected in EDTA
tubes from all subjects and kept at 270uC until
use. DNA was extracted from whole blood using
standard proteinase K digestion and phenol–
chloroform extraction.
CTLA-4 GENOTYPING
The CTLA-4 SNPs were examined by PCR-restric-
tion fragment length polymorphism (RFLP) analy-
sis with restriction endonucleases according to the
method described previously.15 Briefly, PCR pro-
ducts of 21661, 2318 +49 and CT60 polymorph-
isms were respectively digested with 2 U of MseI,
MseI, BstEII and NcoI restriction enzyme (MBI
Fermentas, Vilnius, Lithuania) in a 10 ml reaction
volume overnight. Digestion products were visua-
lised on agarose gels of appropriate concentration
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and stained with GoldView (SBS Genetech, Beijing) (fig 1).
Appropriate controls (no template and known genotype) were
included in each typing run.
STATISTICAL ANALYSIS
SPSS software (version 10.0; SPSS, Chicago) was used to analyse
the data. The software Haploview 3.32 was used for testing
pairwise linkage disequilibrium and to estimate the haplotype
frequency.16 The default setting, confidence interval algorithm,
was applied to our analysis. The allele and genotype distribu-
tions of SNPs in CTLA-4 were compared between patients and
controls by x2 test and Fisher exact correction. Allele and
genotype distributions were also analysed between patients
with or without certain clinical features by x2 test. A p value of
,0.05 was considered significant. A meta-analysis was per-
formed using the Review Manager software package (version
4.2) (http://www.cc-ims.net/RevMan).
RESULTS
Allele and genotype frequencies of CTLA-4
All samples from 228 BD patients and 207 controls were
genotyped for four SNPs in the CTLA-4 gene. The distribution
of genotype frequencies of each SNP in our cohort was in
Hardy–Weinberg equilibrium. Table 2 summarises the results
from our study. There were no differences in the allele or
genotype frequencies of the four SNPs between BD patients and
controls. Furthermore, no association was observed when BD
patients were subdivided according to sex, extraocular clinical
features and HLA-B51 (data not shown).
Haplotype frequencies of CTLA-4
Haplotypes were calculated with the program Haploview 3.32.
Four SNPs were in tight linkage disequilibrium with each other.
Three haplotypes were obtained which have a frequency of
more than 3% in the patient or control group (table 3). As
reported previously,15 the haplotype 21661A:2318C:+49G:
CT60G was the most prevalent haplotype. There were no
differences in haplotype frequencies between the patients and
the controls (table 3). Stratification of patients by sex,
extraocular manifestations and HLA-B51 did not reveal any
correlation between these three haplotypes and subgroups of
patients (data not shown).
Meta-analysis of CTLA-4 polymorphism
For a meta-analysis, we searched the Medline database and
checked the reference lists of the retrieved articles for all studies
which tested the association between CTLA-4 polymorphism
and BD patients. Three studies were found and included in this
meta-analysis. Two studies were from Turkey, and one study
included Caucasian patients (table 4). The association between
SNP +49 and BD patients was assessed using the data from
these three studies as well as the present study. Genotype
frequencies of SNP +49 in these four cohorts were in Hardy–
Weinberg Equilibrium, and there was no heterogeneity among
these studies (p = 0.60, I2 = 0%). The pooled OR was 0.98 (0.83
to 1.15) for fixed effects. The results showed no association
between CTLA-4 SNP +49 and BD (overall effect: Z = 0.26,
p = 0.79).
DISCUSSION
In this study, we examined the association between CTLA-4
polymorphisms and BD in a Chinese Han population. Our
results showed no association between CTLA-4 SNPs and BD or
between haplotypes and BD. There was also no association
between CTLA-4 polymorphisms and BD after stratification by
clinical features. Meta-analysis using data from four studies also
showed no association between CTLA-4 SNP +49 and BD.
Table 1 Clinical findings of patients with Behc¸et disease
Total no with Behc¸et
disease (228) Percentage (100%)
Male 189 82.9
Female 39 17.1
Age at onset (years (SD)) 30.04 (8.95) –
Uveitis 227 99.6
Oral ulcer 218 95.6
Genital ulcer 96 42.1
Hypopyon 52 22.8
Skin lesions 111 48.7
Positive pathergy test 80 35.1
Arthritis 60 26.3
Figure 1 Example of the different
genotype of four SNPs (A) 21661A/G:
lane M, molecular size standard; lane 1,
genotype GG (485 bp); lanes 2, 4 and 5,
genotype AA (322 bp and 163 bp); and
lanes 3 and 6, genotype AG (485 bp,
322 bp and 163 bp). (B) 2318C/T: lanes
1 and 3, genotype CT (577 bp and
483 bp); lane 2, genotype TT (483 bp);
and lanes 4, 5 and 6, genotype CC
(577 bp). (C) CT60G/A: lanes 1 and 4,
genotype AA (196 bp); lanes 2 and 5,
genotype AG (216 bp and 196 bp); and
lanes 3 and 6, genotype GG (216 bp). (D)
+49G/A: lanes 3 and 4, genotype AA
(130 bp); lanes 5 and 6, genotype AG
(152 bp and 130 bp); and lanes 1 and 2,
genotype GG (152 bp).
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All four SNPs assessed in our study have been previously
shown to be associated with a variety of autoimmune
diseases.8 17 18 Sallakci et al12 showed that the +49A allele and
the AA genotype were significantly higher in BD patients with
ocular or skin involvement. They did not find any association
when comparing all BD patients with controls and concluded
that CTLA-4 is rather a disease modifying than a susceptibility
gene. Studies by Gunesacar et al11 and Bye et al13 however failed
to demonstrate any correlation of CTLA-4 polymorphisms with
BD subgroups that were classified according to clinical features.
Our study also did not support the association between CTLA-4
polymorphisms and BD subgroup stratification by clinical
features. The observed discrepancy between these studies may
result from different genetic backgrounds in the populations
analysed or from sampling error. Meta-analysis has been used to
assess the association between gene polymorphisms and
diseases in different races. Certain studies showed an associa-
tion between CTLA-4 gene polymorphisms and systemic lupus
erythematosus (SLE),19 while other studies did not support these
results.20 Meta-analysis using the data from a variety of studies
showed that there was an association between CTLA-4 gene
polymorphism and SLE.21 We therefore performed a meta-
analysis using the data available in the literature11–13 and those
presented in our study. The results showed that there was no
heterogeneity among the four studies and that CTLA-4 SNP +49
was not associated with BD. This difference in the results
concerning association between CTLA-4 SNP +49 and certain
autoimmune diseases may result from the different pathogen-
esis of these diseases. The Th1/Th2 paradigm varies signifi-
cantly in different diseases. CTLA-4 has been regarded as a
genetic master switch for autoimmunity and plays a critical role
in the Th1/Th2 balance. Therefore, the different associations
between CTLA-4 SNP +49 and autoimmune diseases may lead
to the varied Th1/Th2 paradigms in different diseases.
In a recent study, we showed a significant association of the
CTLA-4 haplotype 21661A:2318C:+49G:CT60G and the G
allele at SNP +49 with the susceptibility to VKH syndrome,
another common uveitis entity in China which is considered an
autoimmune disease mediated by T cells.15 Unexpectedly,
however, no association was found between CTLA-4 poly-
morphisms and BD, another frequent uveitis in China. The
conflicting results may be explained by the different nature of
these two common autoimmune uveitis entities. VKH syn-
drome is a granulomatous inflammation, while BD is in fact a
non-granulomatous inflammation. In addition, although Behc¸et
disease is considered as an autoimmune disease mediated by T
Table 2 Allele and genotype frequencies of cytotoxic T lymphocyte-associated antigen 4 polymorphisms in
Han Chinese Behc¸et disease patients and controls
Single nucleotide
polymorphism
Alleles and
genotypes
Behc¸et disease no
(%) Controls no (%) p Value Odds ratio (95% CI)
21661A/G A 388 (85.8) 352 (85.9) 0.996 0.999 (0.681 to 1.466)
G 64 (14.2) 58 (14.1) 1
AA 165 (73.0) 149 (72.7) 0.935 1.031 (0.669 to 1.588)
AG 58 (25.7) 54 (26.3) 1
GG 3 (1.3) 2 (1.0) 1.397 (0.225 to 8.681)
2318C/T C 390 (86.3) 352 (85.4) 0.721 1.072 (0.731 to 1.573)
T 62 (13.7) 60 (14.6) 1
CC 166 (73.4) 149 (72.3) 0.846 1.071 (0.731 to 1.573)
CT 58 (25.7) 54 (26.2) 1
TT 2 (0.9) 3 (1.5) 0.645 (0.104 to 3.998)
+49G/A A 152 (33.3) 149 (36.2) 0.381 0.883 (0.667 to 1.168)
G 304 (66.7) 263 (63.8) 1
AA 20 (8.8) 26 (12.6) 0.429 0.666 (0.350 to 1.268)
GA 112 (49.1) 97 (47.1) 1
GG 96 (42.1) 83 (40.3) 1.002 (0.671 to 1.495)
CT60G/A A 99 (21.7) 92 (22.2) 0.856 0.971 (0.704 to 1.338)
G 357 (78.3) 322 (77.8) 1
AA 9 (3.9) 11 (5.3) 0.766 0.707 (0.277 to 1.805)
GA 81 (35.5) 70 (33.8) 1
GG 138 (60.6) 126 (60.9) 0.947 (0.634 to 1.413)
Allele and genotypes frequencies were compared between Behc¸et disease and control by x2 tests. Single nucleotide polymorphism
(SNP) 21661A/G was not identified successfully in four samples; SNP 2318C/T was not identified successfully in three samples;
and SNP +49G/A was not identified successfully in one sample.
Table 3 Frequency of the cytotoxic T lymphocyte-associated antigen 4 haplotypes (21661, 2318, +49 and
CT60) constructed using the program Haploview 3.32
Haplotypes* Behc¸et disease (%){ Controls (%){ x2{ p Value{ OR (95% CI){
ACGG 288.7 (63.3) 252.1 (60.9) 0.580 0.446 1.11 (0.846 to 1.464)
ACAA 85.3 (18.6) 80.3 (19.4) 0.066 0.797 0.96 (0.681 to 1.343)
GTAG 55.3 (12.1) 53.9 (13.0) 0.191 0.662 0.91 (0.612 to 1.366)
Haplotypes with a frequency less than 3% are not listed.
*Haplotypes were constructed from single nucleotide polymorphisms in the order of 21661A/G, 2318C/T, +49G/A and CT60G/A
using the Haploview 3.32 software based on an accelerated EM algorithm.
{Haplotype numbers and frequencies were estimated using the Haploview 3.32 software.
{The percentages of Behc¸et disease and controls with a certain haplotype were compared with the percentages of Behc¸et disease
and controls without this kind haplotype using the x2 test (262 table).
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cells, it is still proposed that it may represent an autoinflam-
matory condition developing in the background of enhanced
innate immune reactivity.22 23
In conclusion, all results in our study failed to demonstrate
any association of tested CTLA-4 gene polymorphisms with BD
in Chinese patients.
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